Lung Cancer

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Inga T. Lennes, MD, MBA, MPH, medical director, Ambulatory Services, director of clinical quality, Massachusetts General Hospital Cancer Center, discusses aspects of lung cancer screening.

Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses the numerous ALK inhibitors available in the treatment of ALK-positive non–small cell lung cancer, ongoing efforts to combat resistance, and sequencing challenges that have emerged.

Durvalumab combined with standard etoposide and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard chemotherapy alone as a first-line treatment in patients with extensive-stage small cell lung cancer, meeting the primary endpoint of the phase III CASPIAN trial (NCT03043872).

Paul K. Paik, MD, discussed using tepotinib—a highly selective, ATP-competitive, reversible, potent MET TKI—to treat patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses emerging treatment approaches in small cell lung cancer (SCLC).

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung cancer.

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the phase III PACIFIC-2 trial in stage III non–small cell lung cancer (NSCLC).